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Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Norepinephrine 
Reuptake Inhibitors Use and Risk of Fractures in Adults:  
A Systematic review and Meta-Analysis 
 
Vladimir Khanassov, Jingyi Hu, David Reeves, Harm van Marwijk 
Objective: to evaluate the association between SSRI and SNRI use and risk of fractures in older 
adults.  
Methods: We systematically identified and analyzed observational studies comparing 
SSRI/SNRI use for depression with non-SSRI/SNRI use with a primary outcome of risk of 
fractures in older adults. We searched for studies in MEDLINE, PsycINFO, EMBASE, DARE, 
the Cochrane Library, Web of Science clinical trials research registers from 2011 for SSRIs and 
1990 for SNRIs to November 29, 2016.  
Results: Thirty-three studies met our inclusion criteria, 23 studies were included in meta-
analysis: 9 case-control studies and 14 cohort studies. A 1.67-fold increase in the risk of fracture 
for SSRI users compared to non-users was observed (Relative Risk 1.67, 95% CI 1.56-1.79, 
p=0.000). The risk of fracture increases with their long-term use: within 1 year the risk is 2.9% or 
one additional fracture in every 85 users; within 5 years the risk is 13.4% or one additional 
fracture in every 19 users. In meta-regression we found that the increase in risk did not differ 
across age groups (OR=1.006; p=0.173). A limited number of studies on SNRIs use and the risk 
of fractures prevented us from conducting a meta-analysis.  
Conclusions: Our systematic review showed an association between risk of fracture and the use 
of SSRIs, especially with increasing use. Age does not increase this risk. No such conclusions 
can be drawn about the effect of SNRIs on the risk of fracture due to a lack of studies.  
 
 3 
Selective Serotonin Reuptake Inhibitors and Selective Serotonin and Norepinephrine 
Reuptake Inhibitors Use and Risk of Fractures in Adults: A Systematic review and Meta-
Analysis 
Vladimir Khanassov, Jingyi Hu, David Reeves, Harm van Marwijk 
INTRODUCTION 
The treatment most commonly prescribed for depression in older people is an antidepressant.1 
Due to the recurrent nature of depression, this often leads to a long-term prescription. Although 
psychological interventions (e.g., psychotherapy) seem to be more effective than 
antidepressants,2 they are infrequently used in older age groups, for a variety of reasons (e.g., 
convenience, availability, eligibility criteria).2 
According to the National Institute for Health and Clinical Excellence, the first choice of 
antidepressant is a Selective Serotonin Reuptake Inhibitor (SSRI), prescriptions of which have 
shown a 47% increase in recent years, irrespective of age.3 The preference for SSRIs over other 
antidepressants (e.g., tricyclics) is due to their broad indications, safer side effect profile and 
efficacy.4  
However, the use of SSRIs may be associated with a higher risk for all types of fractures 
compared to no SSRI use, which may be a particular concern in older patients.5-8 Several 
guidelines mention the risk of fractures for SSRI use in the elderly: UK guidance on the use and 
safety of SSRIs indicates a small increased risk of fractures;9 and the 2015 update of the Beers 
criteria also lists SSRIs as inappropriate medications in older adults, based on falls risk.10 
Although studies such as the population-based Canadian Multicenter Osteoporosis study showed 
an increased risk which led to a recommendation that bone health be assessed in patients treated 
with SSRIs,11 a recent systematic review of Gebara et al. on the risk of falls could not show 
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causality between SSRI use and the former, stating that there is a lack of evidence to support 
changes in the current treatment guidelines on the use of SSRIs in older adults.12 
Another group of antidepressants that is growing in popularity is Selective Serotonin and 
Norepinephrine Reuptake Inhibitors (SNRIs); however, little is known about their associated risk 
of fractures. This group of medications is increasingly prescribed in the elderly population for the 
treatment of a range of conditions such as depression, anxiety, diabetic neuropathic pain, 
fibromyalgia, and chronic musculoskeletal pain.13 Venlafaxine and Duloxetine are two SNRIs 
that are commonly prescribed. Venlafaxine is now reported to be the sixth most frequently 
prescribed medication for the treatment of depression in older people.14  
Several systematic reviews on the association of SSRI use and risk of fractures have been 
published previously, with the most recent being by Rabenda et al. in 2013.8 We conducted an 
initial scoping review, which found that a considerable number of new, large and higher quality 
studies had been published since, indicating that an updated review would be appropriate. 
Thus, considering an increasing rate of SSRIs and SNRIs prescription, a lack of studies on their 
comparative safety profile in older adults and a considerable number of new published studies 
since the last systematic review, we conducted a systematic review and meta-analysis with meta-
regression. The specific research questions we sought to address were: (1) what is the association 
between SSRI and SNRI use versus non-use, on the risk of fracture in older adults? And (2) what 
is the effect of age on this association? 
METHODS 
We conducted a systematic review and meta-analysis according to the Cochrane 
recommendations.15 The review protocol was registered with the international register of 
systematic review protocols on PROSPERO (CRD42016052926). We used the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) framework for reporting 
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the results.16  
Eligibility criteria 
To be included in our review, studies had to meet the following criteria:  
- Population: adults on an SSRI or SNRI, with or without a formal diagnosis of depression.  
- Exposure: SSRI or SNRI use - Fluoxetine, Citalopram, Escitalopram, Paroxetine, 
Sertraline, Fluvoxamine, Venlafaxine, Duloxetine (a full list is provided in 
Supplementary material). 
- Comparison: none or some other form of anti-depressant treatment. 
- Primary outcome: fracture (any type of fracture at any anatomical sites either self-
reported or identified in the hospital records). 
- Study design: randomized-controlled trials, case-control (e.g., patients with a fracture 
compared to patients without a fracture), cohort studies (e.g., SSRI users compared to non 
SSRI users).  
We included studies using any dose or duration of use of SSRI or SNRI, and recorded these 
factors as potential modifiers of treatment effect. For completeness when searching for studies, 
we also included those comparing SSRIs to SNRIs, different types of SSRIs/SNRIs, and different 
doses of SSRI/SNRI. These studies are described in the text, but have been excluded from any 
pooled statistical analysis (see below). 
 
Search strategy and data sources  
A specialist librarian in systematic reviews assisted with the literature search. We performed a 
systematic search for articles without language restrictions in the following electronic 
bibliographic databases: MEDLINE, PsycINFO, EMBASE, DARE - Database of Abstracts or 
Reviews of Effects, the Cochrane Library (Cochrane Database of Systematic Reviews, Cochrane 
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Central Register of Controlled Trials (CENTRAL), Web of Science (science and social science 
citation index), clinical trials research registers (ClinicalTrails.gov and the WHO’s International 
Clinical Trials Registry Platform). We searched for studies on SSRIs published from April 2011 
(the most recent systematic review on the relationship between SSRIs and fractures included 
studies published up to this date)8 to November 29, 2016. The search for studies on SNRIs ranged 
from 1990 to November 29, 2016. The first SNRI - Venlafaxine was marketed in 1994,17 
therefore we  searched from 4 years prior to the marketing date to ensure that all pre-marketing 
trials were captured. We searched for the studies published in English, French, Dutch or Russian. 
The key words were  “selective serotonin reuptake inhibitor”, “serotonin norepinephrine reuptake 
inhibitor”, “fracture”, “osteoporosis”, “osteopenia”, and “bone mineral density”. (See 
Supplementary material for an example, of the complete MEDLINE search terms).  Additionally, 
reference lists from identified papers and reviews were checked for additional relevant studies. 
All companion articles of the included studies were also examined. If more than one publication 
described the same study, it was treated as one study. The full articles relating to any identified 
conference abstracts were obtained whenever possible. Literature search results were uploaded to 
the Endnote X7 reference management software package.  
Study Selection 
We used a 2-step approach to study selection. First, 2 reviewers (VK, JH) independently 
examined the references (titles and abstracts) based on the eligibility criteria. Second, full texts of 
the selected references were retrieved and read. At each step, differences in coding were resolved 
by consensus. We included conference abstracts if they provided sufficient data.  
Data Collection Process and Items 
One of the reviewers (VK) independently performed data extraction from each study using a 
standardized data collection form that included author, publication date, country, study design, 
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setting, medication type (SSRI, SNRI or both) or specific medication (e.g., Venlafaxine), 
duration of use (current, past), dose (e.g., defined daily dose – DDD), sample size, participant 
characteristics (mean age, male sex, variables controlled in analysis - age, sex, depression, BMD, 
body mass index - BMI, previous fracture, smoking, alcohol, glucocorticoids, number of 
comorbidities, Charlson comorbidity index and others), duration of the study and outcomes such 
as incidence of a new fracture (hip, spine, non-vertebral fractures) and other (e.g., BMD change, 
risk of fracture depending on 5-HTT affinity). Treatment effect estimates for each reported 
outcome were extracted including relative risk (RR) estimates (odds ratio - OR; hazard ratio - 
HR), associated 95% confidence intervals (95% CI), and/or p values. Where more than one effect 
estimate was reported for any outcome, the most stringently adjusted estimate was selected. 
Estimates of fracture risk for current and past SSRI and/or SNRI use were extracted separately, 
and an estimate of current use was used in a meta-analysis to derive an overall estimate across 
studies.11, 18-20 For studies where multiple levels of DDD were investigated, results for the level 
closest to one DDD were selected.19, 21 The primary outcome was fracture at any of the 
anatomical sites assessed in a study, which in most cases included multiple sites (e.g. hip, wrist or 
spine).22-25 Where results were reported for both osteoporotic and non-osteoporotic fractures, 
results for the former were used.26  
One of the authors (DR) checked the form and performed a quality control check by randomly 
selecting 60% of studies and conducting 100% verification of the data collected from these for 
meta-analysis.  
Risk of Bias in Individual Studies 
The quality of each included study was assessed independently by 2 reviewers (VK, JH) using 
the Newcastle-Ottawa scale, designed for case-control and cohort studies.27 Low quality was 
defined as a Newcastle-Ottawa score <7 and high quality as a score ≥ 7 (maximum score 9).5 
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Synthesis of Results 
We summarized the data in tables such as characteristics of included studies for case-control and 
cohort studies. When applying meta-analysis, we made an a priori assumption that studies were 
heterogeneous and adopted the Dersimonian-Laird random-effects model.28 Depending on their 
design, studies reported effect sizes as odds-ratios, hazard ratios, relative risks or standardized 
incidence ratios, but for analysis purposes we treated all forms of effect as approximating an RR 
and amenable to pooling since the baseline incidence rate of fractures was typically low. We 
combined effect estimates across case-control and cohort studies but also included a comparison 
between these designs. The I2 statistic was used to measure heterogeneity. Analysis was 
conducted using the Stata v14 Metan and Metareg commands using an alpha value for statistical 
significance of 5%.29 
Meta-analyses 
For our primary meta-analysis, we pooled studies regardless of the type(s) of SSRIs used or the 
site(s) of fracture studied, but restricted the comparison to non- or past-users of SSRIs (e.g., we 
excluded studies directly comparing different anti-depressants). We also conducted a sensitivity 
analysis using only the studies rated as high quality (NOS score ≥7) and subgroup meta-analyses 
(See Table S4). 
Meta-regression 
There was wide variation between studies in participant age profiles, ranging in means from 43 
years to 78 years. Therefore to investigate the relationship between age and risk of fracture when 
using SSRIs, we conducted meta-regression analyses of (log) effect sizes on the average age 
(usually mean age but for one study the median30) of the participants in each study. We then 
repeated this analyses including study design (cohort or case-control) and percentage male 
participants as covariates. Due to the limited number of studies for meta-regression, we did not 
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include any further study-level covariates. 
Number needed to harm 
To estimate the number of additional users of SSRIs associated with one additional case of 
fracture (number needed to harm, or NNH) we used as a baseline the absolute rates of people 65 
years and over not on anti-depressants experiencing a fracture, of 1.76% over 1 year, 3.26% over 
two years and 8.06% over 5 years, reported by Coupland et al.31 These rates are based on analysis 
of patient records for 570 general practitioners practices from the QResearch primary care 
database. QResearch is reported to be reasonably representative of the UK primary care 
population.14 
Risk of Bias Across Studies 
To examine the potential for publication bias amongst the final set of included studies, we 
produced a funnel plot, plotting the study standard errors against the logarithm of the risk ratios, 
as per the Cochrane recommendations. 
 
RESULTS 
We identified 2,122 articles in the initial search, of which we reviewed 141 full articles (Figure 
1). Our final sample consists of thirty-three studies: 11 case-control studies and 22 cohort studies. 
No relevant randomized controlled studies were found. Sixteen studies were included from the 
previous systematic review20-26, 30, 32-39 and 17 studies were identified as new in the databases 
(Figure 1).11, 18, 19, 31, 40-52 
The studies we found were published between 199837 and 2016, 19, 42-44, 49 with eleven studies 
since 2013.11, 19, 40, 41, 43-46, 48, 49, 52 Two studies were reported across multiple articles and each was 
treated as a single distinct study: Vestergaard et al.21, 53, 54 and Souverein et al.49, 55, 56 One study 
reported results from both a cohort49, 55 and a nested case-control analysis.49, 56 Estimates of effect 
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size were very similar, but for meta-analyses where both sets of results were available we kept 
those from the cohort analysis, as precision was higher, and dropped the case-control results. 
Four conference abstracts were identified.40, 42, 47, 48 All studies were published in English. The 
characteristics of the included studies are presented in Table 1 and 2.  
Study characteristics 
Participants: In the 11 case-control studies, the numbers of case and control subjects ranged from 
3449 to 14,95853 and from 41234 to 373,96221 respectively. In the 22 cohort studies, the numbers 
of participants ranged from 1820 to 906,42241 and the mean follow-up period from 6 months47 to 
10 years.11 Five studies concerned patients with depression only and one, people with 
Parkinson’s disease. Eight studies reported depression status based on a validated depression 
assessment tool (e.g., the geriatric depression scale). Nine and three studies respectively 
concerned only women or only men. Three studies examined the incidence of fractures for 
different age groups of participants.  
SSRI and SNRI: 29 studies evaluated the effect of SSRIs, seven looked at SNRIs, 14, 19, 21, 31, 44, 45, 
47, 48, 53, 54 and two studies grouped these drug classes together. 11, 24 Seven studies provided results 
for specific SSRI or SNRI medications; 14, 19, 31, 35, 42-44, 54 the remainder pooled across different 
medications. Data on SSRI and SNRI use were retrieved either from the national prescription 
database or self-reported and verified from drug containers. Thirteen studies categorized 
participants into current, recent or past users.11, 18-20, 24, 26, 35, 37-39, 41, 43, 52  
Comparisons: Most studies (n=22) used non-users of SSRIs as the comparison group, though 
provided little detail on what other treatments individuals in the comparison group might be 
using. A few studies (n=9) compared SSRIs or SNRIs with other antidepressants (e.g., 
tricyclics),24, 32, 47 SNRIs with SSRIs,45, 48 current with past users,49 individual SSRI medication 
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(Paroxetine) with other SSRIs,42 with SSRIs of different adherence to the treatment50 and no 
comparator description.36 
Outcome: From 33 studies reporting fractures as an outcome, 3 studies reported separately on 
fractures and falls,31, 38, 43 and 2 studies fractures and change in BMD.23, 38  Occurrence of 
fractures was based on hospital records or national health databases, general practice databases, 
self-reporting adjudicated by medical records, and self-reporting. Hip was the most frequently 
reported anatomical site of a fracture followed by non-vertebral fractures and spine.  
Six studies examined fracture incidence relative to SSRI daily dose (DDD) 19-21, 31, 39, 46 and 3 
studies relative to affinity for 5-HTT. 24, 26, 39 Two studies reported the outcome for different 
follow-up periods.45, 52   
Study location: Twelve studies were conducted in Europe (excluding the UK), 11 in the USA, 4 
in the UK, 4 in Canada, 2 in Asia, and one in Israel. Four studies enrolled patients from multiple 
countries. One study included three different cohorts of patients; from the UK, Denmark and 
Spain. 49, 55, 56 The results of these cohorts were used independently in our meta-analyses.  
Quality of the studies: Of the 29 studies (conference abstracts were not included in the quality 
assessment), 26 were high quality (≥7) and 3 low quality (score <7) (Table S2 and Table S3).  
Main meta-analytic results 
Of the 33 studies included in this systematic review, 23 studies were included in the primary 
meta-analysis: 9 case-control studies and 14 cohort studies. Ten studies were dropped from meta-
analysis for reasons of lack of data (one conference abstract), qualitatively different population 
(Parkinson’s disease), poorly matched or non-relevant comparison group (8 studies): see Table 
S1 for the specific reasons for exclusion from the meta-analysis. SSRI use and risk of fracture 
were significantly associated: RR 1.67, 95% CI 1.56-1.79, p=0.001, I2=88.4% (Figure 2). 
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Sensitivity analysis based on only those studies rated as being high quality (n=18) found a very 
similar result: RR 1.68, 95% CI 1.54-1.84, p=0.001, I2=88.4% (Table S4).  
Six studies examined the association between SNRI use and risk of fracture: 2 case-control and 4 
cohort studies (Table S5). Effect of SNRI use was compared to non-use, SSRI use and tricyclics 
use. Two studies evaluated the effect of an individual SNRI (Venlafaxine). We did not conduct a 
meta-analysis on SNRIs due to their excessive heterogeneity and the limited number of studies. 
However, two studies reported a significantly increased risk associated with SNRI use (Table 3).    
Meta-regression 
The meta-regression found no significant relationship between study effect size and average 
participant age, either without (OR=1.006; p=0.173) or with control for design type and gender 
balance (OR=1.006; p=0.175) (Figure 3). Design and gender were themselves not significant 
moderators of effect size (p=0.602 and p=0.640 respectively). 
Subgroup meta-analyses 
Subgroup meta-analyses are presented in Table S4. In most subgroup analyses the number of 
studies was small (<5) and heterogeneity was high. In line with the finding of the meta-
regression, the association between SSRI use and the risk of fracture was similar in both case-
control and cohort studies: RR 1.74, 95% CI 1.50-2.02, p=0.001, I2=92.8% and RR 1.63, 95% CI 
1.49-1.79, p=0.001, I2=84.8% respectively. RRs also varied by only a small degree between 
different anatomical sites of fracture. 
Results for individual SSRI medications were available from only four studies, and subgroup 
analysis showed only small differences in relative risks with widely overlapping confidence 
intervals. However, the effect sizes were all well below the overall RR of 1.67 across all included 
studies, suggesting that this is an unrepresentative subset. 
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For the remaining subgroup analyses, the sub-category level effects likewise had highly 
overlapping confidence intervals in almost all cases, indicating either only small differences or 
that study numbers were too small to detect differences.      
Number needed to harm 
On the basis of the overall pooled relative risk of 1.67 from our meta-analysis and baseline 
absolute fracture rates of 1.76% over 1 year, 3.26% over two years and 8.06% over 5 years,31 the 
estimated fracture rate over one year’s exposure to SSRIs is 2.9% with an NNH of 85; over two 
years 5.4% with NNH=46; and over 5 years 13.4% with NNH=19. 
Publication bias 
The funnel plot was asymmetrical; showing a shortage of smaller studies with lower, possibly 
non-significant, effect sizes. This could indicate a publication bias against such studies (Figure 
4).  
DISCUSSION   
Our meta-analysis showed a pooled 1.67-fold increase in the risk of fracture for older SSRI users 
in comparison to non-users. This level of increased risk is in line with the findings of previous 
systematic reviews,5, 6, 8, 57, 58 but is based on a much larger and higher-quality evidence base. 
SSRIs are typically taken over a long period and the associated risk of fracture within 5 years use 
was 13.4% or one additional fracture in every 19 users. At least part of any increased risk of 
fracture could be related to possible side effects of SSRIs that may be more prominent at their 
initiation: orthostatic hypotension, dizziness, falling, and tachyphylaxis.59-61 However, we found 
that the risk was still significantly elevated over 5 years of use in contrast to the findings of Eom 
et al. who showed a higher risk of fractures with a shorter duration of SSRIs.5  
Despite age having a well-known association with fracture risk,62 in meta-regression we found 
the increase in risk from SSRI use to be much the same in all the studied age groups, from 40 
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years up to 80 years, and the same for males and females. Our meta-analysis thus indicated that 
SSRIs play an independent role from age and gender in increased risk of fracture.6  
Strengths and limitations 
Our systematic review is the most comprehensive review to date on the use of SSRIs (and 
SNRIs) and the risk of fracture. The last meta-analysis on SSRIs was published in 2013 and 
included 16 studies published up to April 2011.8 The great majority of the studies we included 
were individually statistically significant, but nonetheless, there was high heterogeneity in effect 
size and some evidence of possible publication bias against smaller, non-significant studies.  
Although the large majority of studies were rated high quality, the cohort studies generally fell 
down on giving details of exposure, and the case-control studies on details of exposure and non-
response rate.  The control condition was frequently poorly described and differed across studies, 
but in most cases combined non-users of anti-depressants with users of other types of anti-
depressants. This may have led to some degree of underestimation of the fracture risk for SSRIs 
compared to an entirely anti-depressant free population. We did not have individual patient data 
for meta-regression, so were limited to using study mean ages and gender balance, which will 
have limited our power to detect an association with risk. The limited number of the studies on 
SNRIs use and a risk of fracture did not allow us to conduct a meta-analysis and to provide their 
safety profile.  
We found no relevant randomized controlled trials; hence our review is based entirely on 
observational studies that have the potential for bias. We extracted the data adjusted for 
confounders such as osteoporotic risk factors (e.g., BMI, previous fracture), study design, 
methodological quality, age, type of fracture, and duration of the treatment. However, there is 
still a risk of unobserved bias. For example, as Gebara et al. indicate, a study design based on an 
administrative database11, 45 will not adequately capture the diagnosis of depression.12 An absence 
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of randomization in observational studies also introduces the risk of allocation bias. In this 
context, older patients with higher risk of falls tend to have SSRIs or SNRIs prescribed, instead 
of other antidepressants (e.g., tricyclic antidepressants). We found indications of publication bias 
against smaller non-significant studies, but this is unlikely to fully account for our overall result, 
derived mostly from a substantial number of very large observational investigations. 
There were considerable differences in design between studies, including variations in study 
design, populations, comparison groups, SSRI medications, doses and duration, and non-
adjustment (or non-reporting) of important variables. However, we excluded 10 studies from 
meta-analysis that were markedly different in quality of reporting, population, or selection of 
comparison group (e.g., tricyclics). We were limited in our ability to investigate the effects of this 
heterogeneity on study results, due to the number of studies and the available information on 
each. Most of the sub-group analyses were based on very small numbers of studies (2, 3 or 4) and 
results for these should be treated with considerable caution, as the addition of just one extra 
study – particularly given the high heterogeneity - could cause a substantial change in the effect 
estimate or confidence interval.63 
Conclusion 
There is sufficient albeit non-randomized evidence that use of SSRIs substantially increases 
fracture risk in adults, from at least age 40 years and above, particularly when used over long 
periods; but counter to expectations, the degree of increased risk is largely independent of age.  
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Key points 
 SSRIs are the first choice of antidepressants in elderly patients with depression. They are 
associated with higher risk of fractures. Depression plays an independent role in increased risk of 
fractures. 
 Our study found that age does not increase the risk of fractures associated with SSRIs use. 
Long-term use of SSRIs leads to higher risk of fractures.  
 A number of methodological limitations of the published trials suggest the actual risk may be 
higher than our estimate. 
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Figures legends: 
 
Figure 1. Flow Chart 
Figure 2. SSRI use and risk of fracture 
Figure 3. Meta-regression of log effect size on average age of study participants. 
Figure 4. Funnel plot of RR vs standard error of the log 
 
